Symptomatic improvement after mesh removal: a prospective longitudinal study of women with urogynaecological mesh complications.


Journal

BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741

Informations de publication

Date de publication:
11 2021
Historique:
accepted: 30 03 2021
pubmed: 29 5 2021
medline: 18 11 2021
entrez: 28 5 2021
Statut: ppublish

Résumé

To compare clinical characteristics and outcomes in patients undergoing excision of polypropylene urogynaecological mesh for pain, mesh exposure or both. Prospective, longitudinal cohort. Academic tertiary referral centre. Women undergoing complete vaginal mesh excision for mesh exposure and/or pain. Clinical and patient-reported outcomes assessing pain (visual analog scale, VAS), bother (Pelvic Floor Distress Inventory, PFDI) and functional impact (Pelvic Functional Impact Questionnaire, PFIQ) were collected at baseline, 6, 12 and 24 months after complete mesh excision. Outcomes were compared by mesh type (sling, prolapse [transvaginal or sacrocolpopexy mesh], both) and complication (pain, exposure, both). 'Much better' or 'Very much better' on Patient Global Impression of Improvement (PGI-I) up to 2 years after removal. Of 173 women, 48 underwent removal for pain, 27 for exposure and 98 for exposure plus pain. 'Moderate to severe' baseline symptoms were reported by 75%; the most prevalent and severe symptom was dyspareunia. Patients with pain alone were most bothered (PFDI median 234.2, interquartile range 83, P = 0.02) and had the highest functional impact (PFIQ median 181, interquartile range 138, P < 0.001). After excision, only 33.3% of women with pain alone reported 'improved' symptoms (PGI-I), versus 73.9% with exposure, 58.3% with exposure plus pain (P = 0.03) with no differences in PGI-I by mesh type. VAS scores decreased in all groups, but PFDI and PFIQ did not improve in pain patients. In women experiencing a pain complication after urogynaecological mesh insertion, mesh removal often does not improve symptoms. Only 33% of women with pain complications have improved symptoms after urogynaecological mesh removal.

Identifiants

pubmed: 34047446
doi: 10.1111/1471-0528.16778
pmc: PMC8497415
mid: NIHMS1709862
doi:

Substances chimiques

Polypropylenes 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2034-2043

Subventions

Organisme : NICHD NIH HHS
ID : K12 HD043441
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD083383
Pays : United States
Organisme : NIH BIRCWH
ID : K12HD043441
Organisme : NIH/NICHD
ID : 5R01HD083383-03

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 John Wiley & Sons Ltd.

Références

BJU Int. 2016 Feb;117(2):323-43
pubmed: 25906691
Female Pelvic Med Reconstr Surg. 2020 Apr;26(4):244-248
pubmed: 30883438
JAMA. 2013 May 15;309(19):2016-24
pubmed: 23677313
BJOG. 2020 Jul;127(8):1027-1033
pubmed: 32107882
Female Pelvic Med Reconstr Surg. 2015 May-Jun;21(3):176-80
pubmed: 25349942
Female Pelvic Med Reconstr Surg. 2020 Apr;26(4):219-232
pubmed: 32118617
BMC Musculoskelet Disord. 2019 May 18;20(1):234
pubmed: 31103029
Clin Obstet Gynecol. 2015 Dec;58(4):740-53
pubmed: 26512439
Am J Obstet Gynecol. 2003 Jul;189(1):98-101
pubmed: 12861145
Spine (Phila Pa 1976). 2019 Jun 15;44(12):887-895
pubmed: 30601356
J Shoulder Elbow Surg. 2019 Mar;28(3):453-460
pubmed: 30503333
Am J Obstet Gynecol. 2014 Feb;210(2):163.e1-8
pubmed: 24126300
BJOG. 2020 Jan;127(1):88-97
pubmed: 31544327
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
Obstet Gynecol. 2012 Mar;119(3):539-46
pubmed: 22353951
BJOG. 2019 Feb;126(3):419-426
pubmed: 30220104
Female Pelvic Med Reconstr Surg. 2014 May-Jun;20(3):126-30
pubmed: 24763152
Ann Emerg Med. 1996 Apr;27(4):485-9
pubmed: 8604867
J Urol. 2019 Aug;202(2):339-346
pubmed: 30958736
Am J Obstet Gynecol. 2005 Jul;193(1):103-13
pubmed: 16021067
Am J Obstet Gynecol. 2009 May;200(5):580.e1-7
pubmed: 19375574
Am J Obstet Gynecol. 2020 Jun;222(6):588.e1-588.e10
pubmed: 31836546
Int Urogynecol J. 2010 May;21(5):523-8
pubmed: 20013110
Int Urogynecol J. 2013 Feb;24(2):213-21
pubmed: 22669425
Int Urogynecol J. 2014 Jun;25(6):745-9
pubmed: 24318564
Obstet Gynecol. 2011 Sep;118(3):629-636
pubmed: 21860293
Clin Med Insights Reprod Health. 2017 Nov 15;11:1179558117742374
pubmed: 29162981
J Clin Epidemiol. 2003 May;56(5):395-407
pubmed: 12812812
Obstet Gynecol. 2020 May;135(5):1084-1090
pubmed: 32282600
Obstet Gynecol. 2014 Jan;123(1):134-139
pubmed: 24463673
Obstet Gynecol. 2014 Jun;123(6):1201-1206
pubmed: 24807341
J Urol. 2017 Sep;198(3):638-643
pubmed: 28433641
Female Pelvic Med Reconstr Surg. 2018 Jan/Feb;24(1):32-38
pubmed: 28657993

Auteurs

N Pace (N)

University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

A Artsen (A)

Department of Obstetrics, Gynecology & Reproductive Sciences, Women's Center for Bladder & Pelvic Health, UPMC Magee-Womens Hospital, Pittsburgh, PA, USA.
Magee-Womens Research Institute, Pittsburgh, PA, USA.

L Baranski (L)

Department of Obstetrics, Gynecology & Reproductive Sciences, Women's Center for Bladder & Pelvic Health, UPMC Magee-Womens Hospital, Pittsburgh, PA, USA.

S Palcsey (S)

Magee-Womens Research Institute, Pittsburgh, PA, USA.

R Durst (R)

Department of Obstetrics, Gynecology & Reproductive Sciences, Women's Center for Bladder & Pelvic Health, UPMC Magee-Womens Hospital, Pittsburgh, PA, USA.

L Meyn (L)

University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

P A Moalli (PA)

Department of Obstetrics, Gynecology & Reproductive Sciences, Women's Center for Bladder & Pelvic Health, UPMC Magee-Womens Hospital, Pittsburgh, PA, USA.
Magee-Womens Research Institute, Pittsburgh, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH